Introduction {#S0005}
============

Inflammatory bowel disease (IBD) is characterized by severe and progressive inflammation in the gastrointestinal (GI) tract, and includes the two main clinicopathological subtypes of ulcerative colitis (UC) and Crohn\'s disease (CD). Various medical treatments have been shown to be effective in management of IBD \[[@CIT0001], [@CIT0002]\]. Current medical treatments for IBD generally include sulfasalazine \[[@CIT0003]\], 5-aminosalicylates \[[@CIT0004]\], corticosteroids, immunomodulators \[[@CIT0005], [@CIT0006]\] and biological therapy \[[@CIT0007]\]. Even with optimized medical therapy, 30-40% of patients with UC and 70-80% of patients with CD may need surgery at some point during the course of their disease \[[@CIT0008], [@CIT0009]\]. Although surgery may lead to relief of symptoms and withdrawal of potentially toxic medication, several complications including anastomosis leakage, pelvic abscess, wound infection, small bowel obstruction, bleeding, and faecal incontinence may occur post-operatively \[[@CIT0009]\]. Pre-operative use of immunomodulators and biological agents such as infliximab (IFX) by suppression of the immune response potentially increases the risk for postoperative infectious complications \[[@CIT0009], [@CIT0010]\]. Increase in postoperative infection by other immunomodulators such as glucocorticoids and tacrolimus has been clearly shown \[[@CIT0010]\]. On the other hand, there is clinical evidence that the use of IFX has reduced or delayed surgical interventions in IBD patients \[[@CIT0011], [@CIT0012]\]. A previous meta-analysis of the effect of IFX on short-term post-operative complications in patients with UC has demonstrated that short-term complications were increased by use of IFX but infectious complications and non-infectious complications were not significantly increased separately \[[@CIT0013]\]. In the previous meta-analysis, five studies, published between 1966 and September 2009, were included and the effect of IFX on the rate of colectomy was not analysed.

The aim of this meta-analysis and systematic review was to determine the impact of pre-operative IFX use on the rate of colectomy in patients with IBD. We also intended to evaluate the effect of pre-operative IFX therapy on surgical complications.

Material and methods {#S0006}
====================

Data sources {#S20007}
------------

PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies that investigated the efficacy of IFX on the rate of colectomy and post-operative complications/side effects in patients with IBD. Data were collected from 1966 to February 2011. The search terms were "ulcerative colitis" and "Crohn" and "infliximab" and "colectomy" and also their abbreviations were applied. The terms "surgery" and "operation" and "IBD" were alternative keywords for additional relevant articles. For PubMed, all relevant MeSH terms were used. The final queries were validated by manual review and matching results. The reference lists from retrieved articles were also evaluated to make sure all applicable studies were included. The conference proceedings were also searched. The key outcome of interest was rate of colectomy and post-surgical adverse events.

Study selection {#S20008}
---------------

Studies that investigated the effectiveness and influence of IFX on the rate of colectomy and/or post-operative adverse events in patients with IBD were considered. Operational procedures on side effects such as fistuloplasty were not the outcome of interest and they were excluded. Three reviewers independently reviewed the title and abstract of each article to eliminate duplicates, reviews, case studies, trials that did not have institutional review board approval and uncontrolled trials and those published in languages other than English. Studies which were clinical trials, cohorts and case matched were included. Disagreements between reviewers were resolved by consensus. Data on patients' characteristics, therapeutic regimens, dosage, sample size, trial duration, and outcome measures were extracted.

Assessment of trial quality {#S20009}
---------------------------

The methodological quality of the included clinical trials was evaluated using the Jadad score, which assesses the descriptions of randomization, blinding, and dropouts (withdrawals) in the trials \[[@CIT0014]\] ([Table I](#T0001){ref-type="table"}), using the following dichotomized parameters (yes = 1; no = 0): randomization, whether randomization was described appropriately, double-blinding, whether double blinding was described appropriately, and whether dropouts (withdrawals) were described. The overall Jadad score ranged from 0 to 5 points (score ≤ 2 low quality; ≥ 3 high quality).

###### 

Jadad score of clinical trials

  References            Randomization   Blinding   Withdrawals and dropouts   Total Jadad score
  --------------------- --------------- ---------- -------------------------- -------------------
  Gustavsson *et al.*   1               0          1                          2
  Jarnerot *et al.*     2               2          1                          5
  Sandborn *et al.*     1               1          1                          3

Statistical analysis {#S20010}
--------------------

Data from selected studies were extracted into 2 × 2 tables. All included studies were weighted and pooled. Data were analysed using StatsDirect version 2.7.8. Odds ratio (OR) and 95% confidence intervals (95% CI) were calculated using the Mantel-Haenszel and Der Simonian-Laird methods. The Cochran Q test was used to test heterogeneity. The event rate in the experimental (intervention) group against the event rate in the control group was calculated using L\'Abbe plot as an aid to explore the heterogeneity of effect estimates. Funnel plot analysis was used as a publication bias indicator.

Results {#S0011}
=======

The electronic searches yielded 664 items; 113 from PubMed, 17 from Cochrane Central, 51 from Web of Science, and 483 from Scopus. Of these, 14 articles were scrutinized in full text. Two reports were considered ineligible. The included studies comprised 3 randomized clinical trials (RCTs), 8 cohort, and one case-matched retrospective study. In RCTs, 818 patients with UC were randomized to receive IFX or placebo \[[@CIT0012], [@CIT0015], [@CIT0016]\]. Cohort studies represented 1915 patients, of whom 336 were treated with IFX \[[@CIT0009]--[@CIT0011], [@CIT0017]--[@CIT0021]\]. In one case-matched retrospective study, 46 out of 92 patients were treated with IFX \[[@CIT0022]\] ([Table II](#T0002){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}).

![Flow diagram of the study selection process](AMS-7-18050-g001){#F0001}

###### 

Characteristics of studies included in the meta-analysis

  References                           Type of study                      Inclusion criteria                    Number of patients   Concomitant therapy   Duration of IFX therapy                     Dosage of IFX                                                   
  ------------------------------------ ---------------------------------- ------------------------------------- -------------------- --------------------- ------------------------------------------- --------------------------------------------------------------- ---------------
  Ferrante *etal*. \[[@CIT0009]\]      Cohort                             UC IBD type unclassified              141                                        AZA, 6-MP, MTX, CsA, CS                     12 weeks prior to primary                                       NA
  22                                   119                                                                                                                                                                                                                             
  Gustavsson *et al.* \[[@CIT0015]\]   RCT                                Steroid refractory UC                 45                                         Immunomodulator, 5-ASA                      Data not available                                              5 mg/kg
  24                                   21                                                                                                                                                                                                                              
  Mor *et al.* \[[@CIT0022]\]          Case matched retrospective study   UC, indeterminate colitis             92                                         S, CsA, 6-MP                                More than 16 week preoperatively                                NA
  46                                   46 matched                                                                                                                                                                                                                      
  Kunitake *et al.* \[[@CIT0010]\]     Cohort                             UC, CD, indeterminate colitis         413                                        CS, AZA, 6-MP                               12 weeks before surgery                                         5 or 10 mg/kg
  101                                  312                                                                                                                                                                                                                             
  Marchal *et al.* \[[@CIT0017]\]      Cohort                             CD                                    79                                         AZA, CS, ASA, MTX, antibiotic, budesonide   Data not available                                              5 mg/kg
  40                                   39                                                                                                                                                                                                                              
  Bordeianou *et al.* \[[@CIT0011]\]   Cohort                             Ulcerative or indeterminate colitis   171                                        CS, 6-MP, imuran, AZA                       Within 12 weeks prior to surgery                                NA
  44                                   127                                                                                                                                                                                                                             
  Schluender *et al.* \[[@CIT0018]\]   Cohort                             UC                                    151                                        CS, 6-MP, 6-TG, CsA                         Median of two (range 1--12) months before surgery               NA
  17                                   134                                                                                                                                                                                                                             
  Colombel *et al*. \[[@CIT0019]\]     Cohort                             CD                                    270                                        CS, immunomodulator                         Within 8 weeks before surgery or within 30 days after surgery   5 mg/kg
  52                                   218                                                                                                                                                                                                                             
  Appau *et al.* \[[@CIT0020]\]        Cohort                             CD                                    389                                        ASA, AZA, MTX, 6-MP, CS                     Data not available                                              NA
  60                                   329                                                                                                                                                                                                                             
  Selvasekar *et al.* \[[@CIT0021]\]   Cohort                             Chronic UC                            301                                        CS, AZA, 5-ASA                              2-6 months prior to the surgery                                 NA
  47                                   254                                                                                                                                                                                                                             
  Jarnerot *et al.* \[[@CIT0016]\]     RCT                                UC                                    45                                         CS                                          3 months                                                        4-5 mg/kg
  24                                   21                                                                                                                                                                                                                              
  Sandborn *et al.* \[[@CIT0012]\]     RCT                                UC                                    728                                        CS, AZA, 6-MP, 5-ASA                        54 weeks                                                        5 or 10 mg/kg
  484                                  244                                                                                                                                                                                                                             

RCT -- randomized controlled trial, UC -- ulcerative colitis, CD -- Crohn\'s disease, 5-ASA -- 5-aminosalicylates, CS -- corticosteroids, AZA -- azathioprine, 6-MP -- 6-mercaptopurine, CsA -- cyclosporine A, 6-TG -- 6-thioguanine, MTX -- methotrexate, NA -- not available

Effectiveness of infliximab compared to placebo in colectomy in patients with ulcerative colitis {#S20012}
------------------------------------------------------------------------------------------------

The summary RR for colectomy in 3 RCTs \[[@CIT0012], [@CIT0015], [@CIT0016]\] was 1.17 with a 95% CI of 0.6-2.28 and a non-significant RR (*p* = 0.65, [Figure 2 A](#F0002){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (*p* = 0.02, [Figure 2 B](#F0003){ref-type="fig"}) and could not be combined. Thus the random effects for individual and summary of RR was applied. Regression of normalized effect vs. precision for all included studies for colectomy among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled relative risk for the outcome of "colectomy" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g002){#F0002}

![Heterogeneity indicators for the outcome of "colectomy" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g003){#F0003}

Post-colectomy complications in patients who received IFX compared to those who did not {#S20013}
---------------------------------------------------------------------------------------

### Mortality

Summary OR of mortality in seven observational studies \[[@CIT0009]--[@CIT0011], [@CIT0017], [@CIT0018], [@CIT0021], [@CIT0022]\] was 3.34 with a 95% CI of 0.94-11.86, a non-significant OR (*p* = 0.09, [Figure 3 A-a](#F0004){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogeneous (*p* = 0.97, [Figure 3 A-b](#F0005){ref-type="fig"}) and could be combined; thus the fixed effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies for mortality among IFX vs. placebo therapy was --0.75 (95% CI = --2.94 to 1.45, *p* = 0.42) and Kendall\'s test on standardized effect vs. variance indicated tau = --0.14, *p* = 0.56 ([Figure 3 C](#F0006){ref-type="fig"}).

![Individual and pooled odds ratio for the outcome of "mortality" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g004){#F0004}

![Heterogeneity indicators for the outcome of "mortality" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g005){#F0005}

![Publication bias indicators for the outcome of "mortality" in the observational studies considering IFX compared to placebo therapy](AMS-7-18050-g006){#F0006}

Summary RR of mortality in 3 RCTs \[[@CIT0012], [@CIT0015], [@CIT0016]\] was 0.74 with a 95% CI of 0.08-6.83, a non-significant RR (*p* = 0.79, [Figure 3 B-a](#F0007){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogeneous (*p* = 0.97, [Figure 3 B-b](#F0008){ref-type="fig"}) and could be combined; thus the fixed effects for individual and summary of RR was applied. Regression of normalized effect vs. precision for all included studies for mortality among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled relative risk for the outcome of "mortality" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g007){#F0007}

![B-b. Heterogeneity indicators for the outcome of "mortality" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g008){#F0008}

### Hospitalization

Summary RR of hospitalization in two RCTS \[[@CIT0012], [@CIT0015]\] was 0.61 with a 95% CI of 0.44-0.86, a significant RR (*p* = 0.005, [Figure 4 A](#F0009){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are homogeneous (*p* = 0.31, [Figure 4 B](#F0010){ref-type="fig"}) and could be combined but because of few included studies, the random effects for individual and summary of RR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of hospitalization among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled relative risk for the outcome of "hospitalization" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g009){#F0009}

![Heterogeneity indicators for the outcome of "hospitalization" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g010){#F0010}

### Infectious complication

Summary OR of infectious complication in nine observational studies \[[@CIT0009]--[@CIT0011], [@CIT0017]--[@CIT0022]\] was 1.56 with a 95% CI of 0.71-3.44, a non-significant OR (*p* = 0.27, [Figure 5 A-a](#F0011){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (*p* \< 0.0001, [Figure 5 A-b](#F0012){ref-type="fig"}) and could not be combined; thus the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of infectious complication among IFX vs. placebo therapy was --1.08 (95% CI = --6.02 to 3.86, *p* = 0.62) and Kendall\'s test on standardized effect vs. variance indicated tau = --0.11, *p* = 0.61 ([Figure 5 C](#F0013){ref-type="fig"}).

![Individual and pooled odds ratio for the outcome of "infectious complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g011){#F0011}

![Heterogeneity indicators for the outcome of "infectious complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g012){#F0012}

![Publication bias indicators for the outcome of "infectious complication" in the observational studies considering IFX compared to placebo therapy](AMS-7-18050-g013){#F0013}

Summary RR of infectious complication in two clinical trials \[[@CIT0015], [@CIT0016]\] was 0.37 with a 95% CI of 0.09-1.44, a non-significant RR (*p* = 0.15, [Figure 5 B-a](#F0014){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.9013, [Figure 5 B-b](#F0015){ref-type="fig"}) and could be combined but because of few included studies, the random effects for individual and summary of RR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of infectious complication among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled odds ratio for the outcome of "infectious complication" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g014){#F0014}

![Heterogeneity indicators for the outcome of "infectious complication" in the clinical trials considering IFX vs. placebo therapy](AMS-7-18050-g015){#F0015}

### Early post-operative complication

Summary OR of early post-operative complication in two observational studies \[[@CIT0017], [@CIT0022]\] was 2.11 with a 95% CI of 1.02-4.36, a significant OR (*p* = 0.04, [Figure 6 A](#F0016){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.34, [Figure 6 B](#F0017){ref-type="fig"}) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of early post-operative complication among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled odds ratio for the outcome of "early post-operative complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g016){#F0016}

![Heterogeneity indicators for the outcome of "early post-operative complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g017){#F0017}

### Late post-operative complication

Summary OR of late post-operative complication in two observational studies \[[@CIT0017], [@CIT0022]\] was 1.57 with a 95% CI of 0.8-3.06, a non-significant OR (*p* = 0.19, [Figure 7 A](#F0018){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.49, [Figure 7 B](#F0019){ref-type="fig"}) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of late post-operative complication among IFX vs. placebo therapy could not be calculated because of too few included studies.

![Individual and pooled odds ratio for the outcome of "late post-operative complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g018){#F0018}

![Heterogeneity indicators for the outcome of "late post-operative complication" in the observational studies considering IFX vs. placebo therapy](AMS-7-18050-g019){#F0019}

Post-operative side effects in patients with inflammatory bowel disease who took infliximab pre-operatively and those who did not {#S20019}
---------------------------------------------------------------------------------------------------------------------------------

### Anastomotic leak

Summary OR for anastomotic leak in seven observational studies \[[@CIT0009]--[@CIT0011], [@CIT0017], [@CIT0020]--[@CIT0022]\] was 1.71 with a 95% CI of 1.02-2.87, a significant OR (*p* = 0.05) ([Table III](#T0003){ref-type="table"}). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.07) and could be combined; thus the fixed effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of anastomotic leak among IFX vs. placebo therapy was --1.69 (95% CI = --5.29 to 1.92, *p* = 0.28) and Kendall\'s test on standardized effect vs. variance indicated tau = --0.43 (*p* = 0.14).

###### 

Post-operative side effects in patients with IBD who took IFX before operation and those who did not

  Side effects                   OR/RR combined meta-analysis   CI           Value of *p* for OR/RR   Value of *p* for heterogeneity   Publication bias
  ------------------------------ ------------------------------ ------------ ------------------------ -------------------------------- ------------------
  Anastomotic leak               OR: 1.71                       1.02-2.87    0.05                     0.07                             No
  Pelvic abscess                 OR: 1.09                       0.17-6.93    0.93                     0.15                             NA
  Pouch-related complication     OR: 2.06                       1.16-3.66    0.023                    0.054                            NA
  Wound infection                OR: 1.96                       0.84-4.62    0.19                     0.29                             NA
  Other infections               OR: 1.53                       0.41-5.67    0.53                     0.005                            No
  RR: 1.06                       0.16-6.87                      0.95         0.48                     NA                               
  Small intestinal obstruction   OR: 0.44                       0.12-1.64    0.22                     0.83                             NA
  GI complications               RR: 4.17                       0.48-35.94   0.19                     0.96                             NA
  Sepsis                         OR: 1.85                       1.15-2.97    0.02                     0.054                            No
  Postoperative haemorrhage      OR: 2.24                       0.42-11.85   0.34                     0.67                             NA
  Thrombotic event               4.56                           1.12-18.53   0.03                     0.94                             NA
  Ileus                          OR: 0.95                       0.19-4.68    0.95                     0.42                             NA
  Wound failure                  1.27                           0.15-10.55   0.82                     0.78                             NA
  Intra-abdominal abscess        1.85                           0.79-4.3     0.16                     0.5                              NA

NA -- not applicable

### Pelvic abscess

Summary OR for pelvic abscess in two observational studies \[[@CIT0009], [@CIT0021]\] was 1.09 with a 95% CI of 0.17-6.93, a non-significant OR (*p* = 0.93). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.15) and could be combined but because of few included studies the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of pelvic abscess among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Pouch-related complications

Summary OR for pouch-related complications in three observational studies \[[@CIT0009], [@CIT0021], [@CIT0022]\] was 2.06 with a 95% CI of 1.16-3.66, a significant OR (*p* = 0.023). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.054) and could be combined; thus the fixed effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies for pouch-related complication among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Wound infection

Summary OR for wound infection in three observational studies \[[@CIT0009], [@CIT0017], [@CIT0021]\] was 1.96 with a 95% CI of 0.84-4.62, a non-significant OR (*p* = 0.19). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.29) and could be combined; thus the fixed effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of wound infection among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Other infections

Summary OR for other infections in four observational studies \[[@CIT0009], [@CIT0010], [@CIT0017], [@CIT0021]\] was 1.53 with a 95% CI of 0.41-5.67, a non-significant OR (*p* = 0.53). The Cochrane Q test for heterogeneity indicated that the studies are heterogeneous (*p* = 0.005) and could not be combined; thus the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of other infections among IFX vs. placebo therapy was --0.65 (95% CI = --13.35 to 12.05, *p* = 0.85) and Kendall\'s test on standardized effect vs. variance indicated tau = 0, *p* = 0.75.

Summary RR for other infections in two clinical trials \[[@CIT0015], [@CIT0016]\] was 1.06 with a 95% CI of 0.16-6.87, a non-significant RR (*p* = 0.95). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.48) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of other infections among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Small intestinal obstruction

Summary OR for small intestinal obstruction in two observational studies \[[@CIT0017], [@CIT0022]\] was 0.44 with a 95% CI of 0.12-1.64, a non-significant OR (*p* = 0.22). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.83) and could be combined but because of few included studies the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of small intestinal obstruction among IFX vs. placebo therapy could not be calculated because of too few included studies.

### GI complications (nausea, vomiting, dyspepsia, and reflux)

Summary RR for GI complications in two clinical trials \[[@CIT0015], [@CIT0016]\] was 4.17 with a 95% CI of 0.48-35.94, a non-significant RR (*p* = 0.19). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.96) and could be combined but because of few included studies, the random effects for individual and summary of RR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of GI complications among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Sepsis

Summary OR for sepsis in four observational studies \[[@CIT0017], [@CIT0019], [@CIT0020], [@CIT0022]\] was 1.85 with a 95% CI of 1.15-2.97, a significant OR (*p* = 0.02). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.054) and could be combined; thus the fixed effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of sepsis among IFX vs. placebo therapy was 1.78 (95% CI = --5.2 to 8.8, *p* = 0.39) and Kendall\'s test on standardized effect vs. variance indicated tau = 0, *p* = 0.75.

### Post-operative haemorrhage

Summary OR for post-operative haemorrhage in two observational studies \[[@CIT0010], [@CIT0022]\] was 2.24 with a 95% CI of 0.42-11.85, a non-significant OR (*p* = 0.34). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.67) and could be combined but because of few included studies the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of postoperative haemorrhage among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Thrombotic event

Summary OR for thrombotic event in two studies \[[@CIT0010], [@CIT0022]\] was 4.56 with a 95% CI of 1.12-18.53, a significant OR (*p* = 0.03). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.94) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of thrombotic event among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Ileus

Summary OR for ileus in two observational studies \[[@CIT0017], [@CIT0022]\] was 0.95 with a 95% CI of 0.19-4.68, a non-significant OR (*p* = 0.95). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.42) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of ileus among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Wound failure

Summary OR for wound failure in two studies \[[@CIT0017], [@CIT0020]\] was 1.27 with a 95% CI of 0.15-10.55, a non-significant OR (*p* = 0.82). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.78) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of wound failure among IFX vs. placebo therapy could not be calculated because of too few included studies.

### Intra-abdominal abscess

Summary OR for intra-abdominal abscess in three studies \[[@CIT0011], [@CIT0017], [@CIT0020]\] was 1.85 with a 95% CI of 0.79-4.3, a non-significant OR (*p* = 0.16). The Cochrane Q test for heterogeneity indicated that the studies are not heterogeneous (*p* = 0.5) and could be combined but because of few included studies, the random effects for individual and summary of OR was applied. Regression of normalized effect vs. precision for all included studies in the outcome of intra-abdominal abscess among IFX vs. placebo therapy could not be calculated because of too few included studies.

Discussion {#S0033}
==========

The present meta-analysis found that there is no significant difference in the rate of colectomy in the patients with UC who received IFX in comparison to the patients who did not receive IFX. Mortality was not significantly different between the two groups either. However, the level of post-operative hospitalization in patients who were under IFX therapy was lower than in the control group.

There has been no meta-analysis addressing the effect of IFX therapy on the rate of colectomy. Wihelm *et al.* mentioned the efficacy of IFX in their review \[[@CIT0023]\]. However, among the articles included in that review, only Jarnerot *et al.* studied the effect of IFX on the rate of colectomy and found that 21% of the IFX group required colectomy within the first 90 days after treatment in comparison to 67% in the placebo group (*p* = 0.017) \[[@CIT0016]\]. Gustavsson *et al.* found that colectomy in short term (3 months) and also long term (3 years) is reduced in the IFX group with a colectomy frequency of 50% as compared with 76% in the placebo group in 3 years \[[@CIT0015]\]. However, most of the colectomies were performed during the first 3 months. In the cohort of Schluender *et al.*, two out of 17 patients in the IFX group and 37 out of 134 patients in the non-IFX group underwent colectomy \[[@CIT0018]\]. The RCT of Sandborn *et al.* showed that patients with moderate to severe UC treated with IFX were less likely to undergo colectomy during 54 weeks than those receiving placebo despite concurrent medication. However, that trial due to the long period of follow-up was limited by the colectomy follow-up \[[@CIT0012]\]. Several uncontrolled studies showed that the rate of colectomy in patients under IFX therapy is less than 50% \[[@CIT0024]--[@CIT0027]\]. However, those studies had different duration of follow-up and no control groups. This indicates that for more accurate results on the efficacy of IFX in the rate of colectomy, more controlled trials should be performed.

This meta-analysis also found that overall early post-operative complications were more frequent among patients who received IFX pre-operatively. However, overall infectious complications in clinical trials and also observational studies were not significantly different between patients who were treated with IFX and those who were not. Among side effects, anastomotic leak, pouch-related complications, sepsis and particularly thrombotic events were significantly more common in patients who were treated with IFX pre-operatively. There is a meta-analysis on the effect of IFX on short-term post-operative complications in patients with UC demonstrating that short-term complications increase with the use of IFX but infectious complications and non-infectious complications do not significantly increase \[[@CIT0013]\]. Selvasekar *et al.* found a significantly increased risk for post-operative pouch-specific and infectious complications in 47 UC patients who had been treated with IFX before ileal pouch anal anastomosis compared to 254 control patients. Confounding factors such as age, severity of colitis, concomitant use of immunomodulatory drugs, and corticosteroids were adjusted and still IFX remained an independent predictor of infections \[[@CIT0021]\]. Schluender *et al.* did not find any significant difference in overall post-operative or infectious complications between 17 UC patients who had been treated with IFX before surgery and 134 control patients \[[@CIT0018]\]. Mor *et al*. found that the covariate adjusted odds ratio of early complication for 85 patients with UC or indeterminate colitis in the IFX group was 3.54 times higher than that of 523 patients in the control group \[[@CIT0022]\]. Kunitake *et al.*, who evaluated patients with UC, CD, and indeterminate colitis, did not find any significant difference in development of post-operative infectious complications in 101 patients treated with IFX and 312 patients not treated \[[@CIT0010]\].

Appau *et al.* found that pre-surgical treatment with IFX in patients with CD is associated with increased post-operative sepsis, abscess and re-admissions \[[@CIT0020]\]. However, Marchal *et al.* showed that IFX therapy in patients with CD did not increase the rate of post-operative complications in comparison to patients who did not take IFX \[[@CIT0017]\].

To overcome heterogeneity in our meta-analysis, we pooled studies that assessed UC and CD for post-operative complications. However, the rate of colectomy was only analysed in the patients with UC because CD patients rarely undergo isolated colectomy. Combining the patients with UC and the patients with CD in the analyses may have an influence on the results because of their different clinical course, but there is evidence \[[@CIT0010]\] that the difference in the rate of IFX-associated complications between UC and CD patients is not significant. We analysed clinical trials and observational studies separately. Although observational studies are more realistic, bias is more frequent. On the other hand, the internal validity in RCTs is higher and the external validity is lower. However, we did not find a large difference in the results of observational studies vs. clinical trials. In the mortality and infectious complications, the results were opposite. In the observational studies, mortality and infectious complications were more frequent in the patients under IFX therapy. However, the meta-analysis of both types showed that the differences are not significant in these two variables.

In the included studies, there were some kinds of bias such as unclear duration of IFX therapy and/or concomitant therapies and/or the dosage of IFX that inevitably might affect the results of the meta-analysis. For instance, in some studies, such as those of Mor *et al.* \[[@CIT0022]\], Marchal *et al.* \[[@CIT0017]\], and Selvasekar *et al.* \[[@CIT0021]\], all the patients who had ever been treated with IFX were included in the IFX group regardless of the duration of treatment before surgery. Concomitant drugs may also influence the post-surgical complications such as serious infection seen in CD patients who had been treated with IFX in combination with corticosteroids or narcotic analgesics \[[@CIT0028]\]. In fact, in the majority of the studies that assessed the safety of anti-TNF drugs, the majority of patients were receiving concomitant immunomodulators or corticosteroids that may have increased the risk of opportunistic infection \[[@CIT0029]\]. Moreover, Ferrante *et al.* found that a moderate-to-high dose of corticosteroids but not IFX is associated with short-term post-operative infectious complications \[[@CIT0009]\]. It is notable that microbial infection has a fundamental role in pathogenesis of IBD that cannot be neglected and thus most current management protocols for IBD \[[@CIT0030], [@CIT0031]\] and other forms of colitis \[[@CIT0032]\] suggest the use of antibiotics. Of course, the matter of cytokines and inflammation is too complex. For instance, production of cytokines in chronic inflammation prevents further enhancement of cytokine synthesis triggered by surgery and other normal physiological responses may play roles \[[@CIT0033]\].

Despite some recorded heterogeneity in our meta-analysis, no publication bias was found in the analysis. Funnel plot analysis was used as a publication bias indicator. Funnel plots, that is simple scatter plots of the trials\' effect, estimate their sample size in detecting any bias in the meta-analysis. The funnel plot is based on the fact that precision in estimating the underlying treatment effect will increase as the sample size of component studies increases. Results from small studies will scatter widely at the bottom of the graph. The spread will narrow as precision increases among larger studies. In the absence of bias, the plot should thus resemble a symmetrical inverted funnel \[[@CIT0034]\].

In conclusion, this meta-analysis revealed that although IFX use neither decreases the rate of colectomy nor increases the rate of infectious complications in IBD patients, thrombotic events, ileal pouch complications, sepsis and anastomotic leaks are the complications that were increased in the patients who used IFX. On the other hand, post-operative hospitalization is less frequent in the patients under IFX therapy. The patients with IBD who are under IFX therapy are most of the time refractive to other therapies and their disease is in a severe stage. Thus it is possible that the post-operational complications in the IFX group are associated with the severity of the disease, and while the studies that are included in the meta-analysis are heterogeneous, we cannot consider this as an exclusive result of IFX.

Further clinical trials on the efficacy of IFX in patients with CD and on different types of surgery in patients with IBD are needed for more accurate results.
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